Financings
20/20 Biolabs (AIDX) limits Streeterville conversions on $40,000,000 preferred
20/20 Biolabs, Inc. (Nasdaq: AIDX) signed a standstill with Streeterville Capital, LLC on July 16, 2026 that holds back conversions of its series E preferred for 120 days, a July 22 filing says.

20/20 Biolabs, Inc. (Nasdaq: AIDX) signed a standstill agreement with Streeterville Capital, LLC on July 16, 2026. The agreement limits when the investor may convert its series E convertible preferred stock into common shares. The company disclosed it in a Form 8-K filed on July 22, 2026. The preferred stock traces back to a securities purchase agreement of November 17, 2025, under which the company agreed to offer up to $40,000,000 of series E preferred at $1,000 per share.
Why is this important: The standstill holds back conversions that would put new common shares into a market where the stock has been trading below the $1.00 minimum bid price. The preferred converts at the lower of $11.42 and 89% of the lowest daily volume weighted average price over ten trading days, subject to a floor. For shareholders, the deal carries dilution that resumes when the standstill ends or breaks. For Streeterville, the standstill ends early if the company defaults under the certificate of designation.
Jonathan Cohen, the chief executive, signed the filing. In our view, the terms let the investor set the pace of share issuance. A conversion price tied to a discount on recent trading, with only a floor for protection, gives the holder every reason to convert when the stock is weak. The standstill delays that pressure, but it does not remove it. The company reported cash and cash equivalents of $4,219,099 on March 31, 2026, and its 2025 annual report says its continuation as a going concern depends on continued external financing. We think that leaves the board with few options that do not involve more dilution.
How the preferred stock converts
Each share of series E preferred has a stated value of $1,098.90, and it converts into common stock at the lower of $11.42 and 89% of the lowest daily volume weighted average price on the company's principal market during the ten trading days before the conversion date. The conversion price cannot fall below a floor set at 20% of the Minimum Price, as defined in Nasdaq Rule 5635.
The standstill agreement is dated July 16, 2026. For the 120 days that follow, Streeterville agreed not to seek to convert series E shares into common stock unless the common stock trades at least 10% above the Minimum Price on a given day. The standstill ends immediately if the company breaches it or an Event of Default occurs under the certificate of designation. The 8-K attaches the agreement as Exhibit 10.1. Streeterville Capital, LLC is the investor and the only counterparty named in the filing. The filing names no placement agent, underwriter or financial advisor for this transaction.
The filing also reports a Nasdaq bid price notice. On July 17, 2026, Nasdaq told the company that its closing bid price had been below $1.00 for 30 consecutive business days, from June 3, 2026 to July 16, 2026. The company received a 180-calendar day compliance period, until January 13, 2027, and may be granted a second period if it meets the other initial listing standards.
The lead tests and the cash position
The company's business is laboratory testing. The interim report for the quarter lists OneTest revenue of $310,103, against $471,379 a year earlier. The 2025 annual report describes OneTest for Cancer, a multi-cancer early detection test built mainly on protein tumor markers, and says the company believes that approach detects earlier stage cancers better than tests based on circulating tumor DNA. Those statements are the company's own, and the filings do not name a ClinicalTrials.gov registration for the test.
The March 31, 2026 interim statements show cash and cash equivalents of $4,219,099 and total working capital of $2,120,232. The operating loss for the three months ended March 31, 2026 was $1,443,356. The notes say the statements were prepared assuming the company will continue as a going concern, and that without adequate capital it could be forced to cease operations.
The next dated items are the end of the 120-day standstill, which runs from July 16, 2026, and the January 13, 2027 bid price deadline.
The agreement is described in the Form 8-K filed July 22, 2026. The company's latest interim figures before that date are in the Form 10-Q for the quarter ended March 31, 2026, and the business description is in the Form 10-K for 2025.
Investor Chat
Loading posts…
aibio